PerkinElmer, Inc. Expands Distribution Channel for Spectroscopy and Chromatography Instrumentation Consumables and Minor Accessories with VWR International, Inc.

Shelton, Conn. - PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, and VWR International, LLC, a global laboratory supply and distribution company, have signed an expanded distribution agreement. Working with VWR through this new agreement provides broader and more streamlined ordering options for PerkinElmer’s analytical consumables and minor accessories to the Company’s clients in the academic, pharmaceutical, and analytical testing markets in North America.

For scientists and lab technicians that require the performance and reliability of PerkinElmer-approved consumables and accessories for their PerkinElmer instruments, the new agreement brings greater convenience and efficiency to the ordering process.

The agreement provides laboratory professionals with increased access to thousands of PerkinElmer consumable products and accessories, including PerkinElmer’s analytical instrumentation portfolio of Spectroscopy and Chromatography solutions.

“In today’s busy, cost-conscious laboratory environment, PerkinElmer is focused on providing superior service to customers by offering easy and effective access to our consumables and accessories,” said Andrea Beccari, vice president, Consumables, PerkinElmer. “While customers have always been able to find us through our sales and service professionals and through the web, offering our solutions through VWR’s world class distribution process offers even more convenience and options.”

In addition to a complete line of PerkinElmer inorganic, chromatography and materials characterization consumables, customers of VWR will also be able to order both FT-IR and UV/Vis spectroscopy solutions from PerkinElmer, including the LAMBDATM XLS and LAMBDATM Bio spectrophotometers.

With 150 years of industry experience, VWR offers a well-established distribution network that reaches most of the world’s top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations. VWR has more than 6,500 associates around the world working to streamline the way researchers across North America, Europe and Asia stock and maintain their labs. For more information, or to order PerkinElmer products, contact VWR by phone at 1-800-932-5000 or by visiting www.vwr.com.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of almost $2 billion in 2008, has approximately 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products decline or do not grow as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products may expose us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with health care industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; (21) reduction or elimination of dividends on our common stock; and (22) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

MORE ON THIS TOPIC